Nonpenetrating glaucoma surgery cannot achieve lower target IOP

Article

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Ophthalmology.

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Glaucoma.

Ahmet Hondur, MD of Dinar State Hospital, Turkey and colleagues assessed the impact of nonpenetrating surgery on IOP by reviewing studies on nonpenetrating glaucoma surgery, deep sclerectomy (DS) and viscocanalostomy (VC) (excluding those reporting on combined glaucoma and cataract surgery) from the past five years.

Following primary DS, DS with implant, DS with antimetabolite, primary VC and VC with implant or antimetabolite, cases achieving IOP of ≤21 mmHg were 48.6%, 68.7%, 67.1%, 51.1% and 36.8%, respectively. The research team determined effectiveness in terms of target IOP achievement. For lower set IOP targets, DS and VC success rates were 35 – 86% and 10 – 67%, respectively.

Based on these data, the team concluded that the potential of nonpenetrating surgery to achieve lower target IOPs is low, although this type of surgery can reduce IOP into the high teens.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.